Core Viewpoint - The company has triggered the conditional redemption clause for its convertible bonds, "Qizheng Convertible Bonds," due to the stock price exceeding 130% of the conversion price for fifteen consecutive trading days, leading to a decision for early redemption [2][7]. Group 1: Convertible Bond Redemption Details - The redemption price for "Qizheng Convertible Bonds" is set at 101.701 CNY per bond, which includes accrued interest [9]. - The total issuance of the convertible bonds was 800 million CNY, with each bond having a face value of 100 CNY [2][3]. - The redemption will occur on September 10, 2025, with the redemption registration date being September 2, 2025 [10]. Group 2: Conditions for Redemption - The company can redeem the bonds if the stock price remains above 130% of the conversion price for at least fifteen trading days or if the remaining unconverted bonds are less than 30 million CNY [7][8]. - The conversion price has been adjusted multiple times, with the latest adjustment setting it at 19.01 CNY per share as of July 10, 2025 [7][10]. Group 3: Shareholder Information - The company has confirmed that major shareholders, including the actual controller and significant stakeholders, did not engage in trading the convertible bonds in the six months leading up to the redemption conditions being met [10]. - Shareholders wishing to convert their bonds must do so through the securities company that holds their bonds [11].

Core Points - The company reported a revenue of 1.175 billion yuan for the first half of 2025, representing a year-on-year growth of 16.36% [1] - The net profit attributable to shareholders was approximately 358 million yuan, showing a year-on-year increase of 10.04% [1] - The company plans to distribute a cash dividend of 2.20 yuan per 10 shares, marking the first semi-annual profit distribution since the special dividend in Q3 2024 [1] Financial Performance - Revenue for the reporting period reached 1.175 billion yuan, with a year-on-year growth of 16.36% [1] - Net profit attributable to shareholders was about 358 million yuan, reflecting a year-on-year increase of 10.04% [1] - The company has implemented a total of 17 cash dividend distributions since its listing, with a cumulative cash dividend amounting to 2.895 billion yuan [1] Dividend Policy - The company expects to distribute a total of 123 million yuan in dividends, which accounts for approximately 34.4% of the net profit attributable to shareholders for the first half of 2025 [1] - The company emphasizes the importance of reasonable returns to investors and aims to enhance the stability and sustainability of its cash dividend policy [1] - The company has already distributed a cash dividend of 201 million yuan for the 2024 fiscal year on July 10, 2025 [1]

| | | 西藏奇正藏药股份有限公司 关于提前赎回"奇正转债"的第九次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"奇正转债"赎回价格：101.701元/张（含当期应计利息，当期年利率为 1.80%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有限责任公司 深圳分公司（以下简称"中登公司"）核准的价格为准。 2、赎回条件满足日：2025年8月11日 3、"奇正转债"停止交易日：2025年8月29日 4、"奇正转债"赎回登记日：2025年9月2日 5、"奇正转债"停止转股日：2025年9月3日 6、"奇正转债"赎回日：2025年9月3日 7、发行人（公司）资金到账日（到达中登公司账户）：2025年9月8日 8、投资者赎回款到账日：2025年9月10日 9、赎回类别：全部赎回 10、最后一个交易日可转债简称：Z正转债 11、根据安排，截至2025年9月2日收市后仍未转股的"奇正转债"将被强制 赎回。本次赎回完成后，"奇正转债"将在深圳证券交易所摘牌，特提醒"奇正 转债"债券持有人注意在限期内转股。债券持有人持有的"奇正转债" ...

Financial Performance - The company reported a total revenue of 1.175 billion yuan for the first half of 2025, representing a year-on-year increase of 16.36% [1] - The net profit attributable to shareholders reached 358 million yuan, up 10.04% year-on-year [1] - The gross margin was 82.19%, an increase of 0.37% compared to the previous year, while the net margin decreased by 5.56% to 30.59% [1] - The total of selling, administrative, and financial expenses was 581 million yuan, accounting for 49.42% of revenue, a decrease of 4.76% year-on-year [1] - Earnings per share increased by 9.98% to 0.68 yuan, and operating cash flow per share surged by 991.52% to 0.92 yuan [1] Cash Flow and Receivables - Accounts receivable increased by 43.87% to 480 million yuan, attributed to the credit policy and unexpired collection periods [3] - The net cash flow from operating activities saw a significant increase of 993.71%, mainly due to an increase in bank acceptance bill discounts [3] - The net cash flow from investing activities decreased by 188.2%, due to a reduction in the redemption of financial products [3] Market and Product Strategy - The company is optimistic about the growth potential of its main product, the pain-relief patch, driven by an aging population and the increasing prevalence of chronic diseases [5] - The company plans to expand its product portfolio in the skeletal muscle pain relief sector, focusing on products like Bai Mai Ointment and Ruyi Zhenbao Tablets, which are part of key national research projects [6] - The company aims to enhance its marketing strategy by strengthening its sales channels, including online and offline retail, and focusing on academic and brand marketing to increase brand influence [8][9] Business Model and Future Outlook - The company operates with a multi-product strategy and aims to cover various medical fields, leveraging the unique therapeutic advantages of Tibetan medicine [7] - The long-term vision is to create sustainable value in the traditional medicine sector while expanding into respiratory, neurological, pediatric, and digestive health products [7] - The company emphasizes compliance and academic-driven marketing to enhance product clinical value and competitiveness [9]

Group 1 - The company reported steady growth in its operating performance, achieving revenue of 1.175 billion yuan, a year-on-year increase of 16.36% [1] - Operating profit reached 419 million yuan, reflecting a year-on-year growth of 14.42%, while net profit attributable to shareholders was 358 million yuan, up 10.04% year-on-year [1] - The company plans to distribute a cash dividend of 2.20 yuan (including tax) for every 10 shares to all shareholders [1] Group 2 - The company is guided by a strategic framework of "dual-wheel drive, dual-wing leadership, and dual-foundation assurance," resulting in significant marketing effectiveness across multiple products [1] - Core products in the musculoskeletal system, such as pain relief patches, have maintained market share, while new growth points have emerged from products like Baimai ointment and Ru Yi Zhen Bao tablets [1] - The company has made breakthroughs in core capability construction, optimizing marketing systems and channel efficiency, and advancing smart manufacturing systems as planned [1] Group 3 - In terms of corporate governance, the company focuses on long-term value creation, standardized governance, and professional operations, aiming for a "100 billion yuan Tibetan medicine" strategic goal [2] - The company has been recognized with titles such as "National Civilized Unit" and "Advanced Collective in the National Industrial and Information System" during the reporting period [2] - The company ranked in the top 26 of the "2025 China Traditional Chinese Medicine R&D Strength Ranking" and was listed in the "2025 Golden Bee Corporate Social Responsibility China List" [2]

Group 1 - The company reported a revenue of 1,175,055,354.14 yuan for the first half of 2025, representing a year-on-year growth of 16.36% [2] - The net profit attributable to shareholders of the listed company was 358,394,175.54 yuan, showing a year-on-year increase of 10.04% [2]

（文章来源：证券日报） 证券日报网讯 8月22日晚间，奇正藏药发布公告称，公司第六届监事会第八次会议审议通过了《2025年 半年度利润分配方案》等多项议案。 ...

证券日报网讯 8月22日晚间，奇正藏药发布公告称，公司第六届董事会第十三次会议审议通过了《2025 年半年度报告及摘要》等多项议案。 （文章来源：证券日报） ...

8月22日奇正藏药发布2025半年度分配预案，拟10派2.2元（含税），预计派现金额合计为1.23亿元。派 现额占净利润比例为34.40%，这是公司上市以来，累计第18次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派2.2元（含税） | 1.23 | 0.94 | | 2024.12.31 | 10派3.8元（含税） | 2.01 | 1.75 | | 2024.09.30 | 10派2.2元（含税） | 1.17 | 1.06 | | 2023.12.31 | 10派4.8元（含税） | 2.54 | 1.97 | | 2022.12.31 | 10派3.9元（含税） | 2.07 | 1.48 | | 2021.12.31 | 10派5.9元（含税） | 3.13 | 2.09 | | 2020.12.31 | 10派3.4元（含税） | 1.80 | 1.22 | | 2019.12.31 | 10派3.5元（含税） | 1.86 | 1.40 | | ...

Group 1 - The company, Qizheng Tibetan Medicine, announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 2.20 yuan (including tax) for every 10 shares held by shareholders [1] - The total share capital as of August 21, 2025, is 562,454,256 shares, with 2,092,450 shares in the repurchase account, resulting in a base of 560,361,806 shares for the dividend calculation [1] - The expected total dividend payout amounts to 123,279,597.32 yuan (including tax) [1]